Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,040 across all filing types
Latest filing 2026-05-23 Report Publication Anno…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Newspaper Publication
Report Publication Announcement Classification · 90% confidence The document is a letter to the BSE and NSE under SEBI LODR Regulations 30 and 47 notifying that the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been published in newspapers and posted on the company website. It does not itself contain detailed financial statements but encloses copies of the publication. This is an announcement of report publication rather than the report itself.
2026-05-23 English
Copy of Newspaper Publication
Earnings Release Classification · 78% confidence The document is a stock-exchange filing under SEBI LODR Regulations 33/47 to submit the company’s audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It is not a full annual report (10-K), nor a management discussion (MDA), nor a regulatory certification letter (RNS). Instead, it is the official announcement of periodical financial results (including audited figures and auditor’s report references) – a classic earnings release. Therefore, the appropriate classification is ER (Earnings Release). FY 2026
2026-05-23 English
Earnings Call
Report Publication Announcement Classification · 88% confidence The document is a short regulatory announcement under SEBI LODR 2015 (Regulation 30) informing that the audio recording of the company’s earnings webinar on audited financial results for the quarter and year ended March 31, 2026 has been uploaded to the company website. It contains no actual financial data or transcript of the call, only an announcement of publication. This matches the definition of a Report Publication Announcement (RPA).
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Report Publication Announcement Classification · 88% confidence The document is a short SEBI Regulation 30 disclosure notifying the stock exchanges (BSE/NSE) that the audio recording of the earnings webinar has been uploaded to the company website. It does not contain financial data or results itself, nor is it a full transcript or presentation; it simply announces the publication of materials. Under the “menu vs meal” rule, this is an announcement of published content rather than the content itself. This fits the definition of Report Publication Announcement (RPA).
2026-05-22 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 78% confidence The document is an intimation under SEBI Listing Regulations (Regulation 30) notifying stock exchanges of a material tax order received by a subsidiary and the company’s plan to appeal. It provides details of the litigation and financial implications. This is not a financial report, earnings release, or management change notice, but an update on legal proceedings under continuous disclosure requirements. It best fits the Legal Proceedings Report category.
2026-05-22 English
Tax Demand order received by company''s step down subsidiary
Legal Proceedings Report Classification · 90% confidence The document is an SEBI Listing Regulation 30 disclosure informing stock exchanges about a tax order and related litigation steps. This is an update on a legal matter (Income-tax order and appeal process). Under our definitions, this best fits “Legal Proceedings Report” (LTR).
2026-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.